Cancer survivors’ stories are welcome good news in a world full of gloom and celebrity tittle tattle. This survivor’s story is remarkable in every sense of that word. His name is Mel Mann. This briefly is his story – Mel was diagnosed with chronic myeloid leukemia in January 1995 and given three years to live. The only possible hope for survival was a bone marrow transplant. Despite numerous marrow drives and adding thousands of people to the marrow registry, he never found a donor. Three years after diagnosis, he entered the phase 1 clinical trial of Gleevec (imatinib) at the University of Texas MD Anderson Cancer Center. Over twenty years later, he is their longest living Gleevec patient. Mel’s full story can be read at…
Leave a CommentStephen Bentley - Writer